Tirzepatide Long-Term Safety Data Reviewed

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

Tirzepatide, the active ingredient in Zepbound and Mounjaro, helped patients lose an average of 20.9% of their body weight over 72 weeks in clinical trials Zepbound vs. Mounjaro comparison.
Zepbound is FDA-approved for chronic weight management and obstructive sleep apnea in adults with obesity, while Mounjaro is approved for type 2 diabetes.
Common side effects include nausea (experienced by 12-22% of patients), diarrhea (12-16%), and vomiting (6-13%).
This medication works by mimicking two gut hormones, GLP-1 and GIP, to manage blood sugar, increase satiety, and reduce appetite.

Tirzepatide is a powerful medication that has changed how we approach chronic weight management and type 2 diabetes. This active ingredient is found in both Zepbound and Mounjaro, though each brand has distinct FDA approvals. In clinical trials, tirzepatide demonstrated remarkable effectiveness for weight loss, with patients at the 15 mg dose achieving an average reduction of 20.9% of their body weight over a 72-week period. This significant weight loss was achieved by activating two key gut hormone receptors, GIP and GLP-1, which work together to regulate blood sugar, increase feelings of fullness, and decrease appetite. While highly effective, patients should be aware of common side effects such as nausea (affecting 12-22% of patients) and diarrhea (experienced by 12-16% of patients), which are typically managed with dietary adjustments. Understanding the mechanisms, benefits, and potential risks of tirzepatide is crucial for anyone considering this treatment option.

What is Tirzepatide and How Does it Work?

Tirzepatide is a unique medication that functions as a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. This means it mimics the actions of two natural hormones found in the gut, which play vital roles in how our bodies manage blood sugar and appetite. This dual action sets tirzepatide apart from some other medications that only target GLP-1. Dr. Eleanor Yusupov, D.O., an assistant professor at New York Institute of Technology’s medical school, explained that "Zepbound is different from Ozempic and other GLP-1s, That’s because it [mimics] two gut hormones — GLP-1 and GIP — to control blood sugar, increase insulin, decrease glucagon (a hormone that raises blood sugar), slow down food leaving the stomach, and regulate appetite." This combined approach allows tirzepatide to influence several physiological processes simultaneously, leading to comprehensive metabolic improvements.

Stimulating Insulin Release and Managing Blood Sugar

One of the primary ways tirzepatide works is by stimulating the release of insulin from the pancreas, but only when blood glucose levels are elevated. This glucose-dependent mechanism is important because it reduces the risk of dangerously low blood sugar (hypoglycemia) compared to some other diabetes medications. When blood sugar rises after a meal, tirzepatide helps the body produce the necessary insulin to bring those levels back down. This targeted action is crucial for improving blood sugar control in individuals with type 2 diabetes. By enhancing the body's natural insulin response, tirzepatide helps to maintain more stable glucose levels throughout the day, preventing the sharp spikes that can damage organs over time. This makes it an effective tool for managing the complex metabolic challenges associated with diabetes, working in harmony with the body's own regulatory systems.

Slowing Gastric Emptying and Increasing Satiety

Tirzepatide also works by slowing down gastric emptying, which means food stays in the stomach for a longer period. This delay in digestion has several benefits. First, it leads to increased satiety, or the feeling of being full for longer. When food moves slowly through the digestive tract, the body has more time to register fullness signals, which can help reduce overall food intake. This mechanism is a key contributor to the weight loss observed with tirzepatide. Second, by slowing gastric emptying, tirzepatide helps to control post-meal sugar spikes. When carbohydrates are absorbed more gradually, blood sugar levels rise more smoothly, preventing the rapid increases that can be challenging for the body to manage, especially in individuals with type 2 diabetes. This effect on gastric emptying helps in both blood sugar control and appetite regulation.

Reducing Glucagon and Improving Insulin Sensitivity

Beyond insulin stimulation and gastric emptying, tirzepatide also reduces the production of glucagon from the liver. Glucagon is a hormone that typically raises blood sugar levels, particularly between meals or during fasting, by signaling the liver to release stored glucose. By decreasing glucagon production, tirzepatide helps to lower overall blood sugar levels, adding another layer of blood glucose control. Furthermore, tirzepatide improves insulin sensitivity. In conditions like type 2 diabetes and obesity, the body's cells can become less responsive to insulin, meaning more insulin is needed to achieve the same effect of moving glucose from the blood into cells. Tirzepatide helps to make cells more sensitive to insulin, allowing the body to use its own insulin more efficiently. This improvement in insulin sensitivity is fundamental to addressing the root causes of metabolic dysfunction.

Regulating Appetite Through Central Nervous System Effects

Another significant way tirzepatide contributes to weight loss is by reducing appetite through its effects on the central nervous system. The GLP-1 and GIP receptors are found not only in the gut but also in the brain. When tirzepatide activates these receptors in the brain, it sends signals that reduce hunger and cravings. This central appetite suppression makes it easier for individuals to adhere to a reduced-calorie diet, as they naturally feel less hungry and more satisfied with smaller portions. Dr. Andrew Shapiro, M.D., a board-certified general surgery specialist, affirmed that "Like Zepbound, Mounjaro mimics the GLP-1 and GIP hormones to help regulate blood sugar, improve insulin production, and promote satiety." This dual hormonal action provides a comprehensive approach to weight management by influencing both metabolic processes and brain signals related to hunger. The combined effects of stimulating insulin, slowing gastric emptying, reducing glucagon, improving insulin sensitivity, and decreasing appetite make tirzepatide a powerful medication for both managing type 2 diabetes and achieving significant weight loss, as highlighted in the study published in the New England Journal of Medicine on its efficacy and safety in people with obesity Tirzepatide for obesity study.

What Are Zepbound and Mounjaro Approved For?

Zepbound and Mounjaro both contain the same active ingredient, tirzepatide, but they have distinct FDA approvals that dictate their primary uses. This difference in approval is crucial for understanding which medication might be appropriate for a given patient and how insurance coverage typically applies. While the underlying mechanism of action is identical—mimicking GLP-1 and GIP hormones—the specific indications for which they received FDA clearance are different.

Zepbound: For Chronic Weight Management and Obstructive Sleep Apnea

Zepbound is FDA-approved for chronic weight management in adults. This approval specifically targets individuals with obesity, defined as having a Body Mass Index (BMI) of 30 kg/m² or greater. It is also approved for adults who are overweight, meaning a BMI of 27 kg/m² or greater, provided they have at least one weight-related condition. These weight-related conditions can include high blood pressure, dyslipidemia (unhealthy levels of fats in the blood), or sleep apnea. Zepbound is intended to be used in combination with a reduced-calorie diet and increased physical activity, emphasizing that it is an aid to lifestyle changes, not a standalone solution. The approval for Zepbound for weight management occurred in 2022.

In a significant update in 2024, Zepbound also received FDA approval to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Obstructive sleep apnea is a serious condition where breathing repeatedly stops and starts during sleep, often due to obesity-related factors. This expanded indication highlights the broader health benefits that can be achieved through tirzepatide-induced weight loss. For individuals struggling with both obesity and OSA, Zepbound offers a dual therapeutic approach, addressing the underlying weight issue that often contributes to sleep apnea. This makes Zepbound a valuable option for improving not just weight but also related health complications.

Mounjaro: For Type 2 Diabetes Treatment

Mounjaro, on the other hand, is FDA-approved for the treatment of type 2 diabetes in adults. Its primary indication is to improve blood sugar control in patients with this condition. Like Zepbound, Mounjaro is meant to be used alongside diet and exercise. The FDA approval for Mounjaro also came in 2022, recognizing tirzepatide's effectiveness in managing glycemic control. For individuals with type 2 diabetes, Mounjaro helps to regulate blood sugar levels through its dual action on GLP-1 and GIP receptors. This includes stimulating insulin release when glucose is high, slowing gastric emptying, reducing glucagon production, and improving insulin sensitivity.

The distinction in approvals means that while Mounjaro can lead to weight loss in patients with type 2 diabetes, its official indication is centered on blood sugar management. This difference impacts how the medication is prescribed and often how it is covered by insurance. Patients with type 2 diabetes can benefit from Mounjaro's ability to help control their blood sugar while also experiencing the secondary benefit of weight reduction, which can further improve their diabetic condition. The medication is administered once a week subcutaneously (under the skin) for both indications, offering a convenient dosing schedule for patients. The fact that both medications contain the same active ingredient, tirzepatide, but serve different primary indications, underscores the versatility of this dual agonist in addressing distinct but often related metabolic health challenges.

How Effective is Tirzepatide for Weight Loss?

Tirzepatide has shown impressive effectiveness for weight loss, particularly in clinical trials designed to assess its impact on chronic weight management. The results from these studies, known as the SURMOUNT trials, have provided clear evidence of its potential. These trials compared the effects of tirzepatide against a placebo, offering a robust measure of its efficacy. The findings consistently pointed to significant and substantial weight reductions in patients treated with the medication.

Detailed Weight Loss Effectiveness from SURMOUNT Trials

Clinical trials have demonstrated that tirzepatide leads to significant weight loss. Specifically, in the SURMOUNT trials, patients who received the 15 mg dose of tirzepatide experienced an average weight loss of 20.9% of their body weight over a period of 72 weeks. This level of weight reduction is substantial and represents a major breakthrough in chronic weight management. To put this into perspective, patients in the placebo group, who did not receive the active medication, only achieved an average weight loss of 3.1% during the same 72-week period. This stark difference highlights the profound impact of tirzepatide on body weight. The study published in the New England Journal of Medicine detailed the efficacy and safety of tirzepatide in people with obesity, underlining these significant outcomes Tirzepatide for obesity study.

The effectiveness extends beyond just average weight loss percentages. The trials also showed that a high percentage of patients achieved clinically meaningful weight loss. A significant weight loss, defined as losing 5% or more of body weight, was achieved by 91% of patients receiving tirzepatide. This indicates that the vast majority of individuals on the medication experienced a noticeable and beneficial reduction in weight. Furthermore, a substantial weight loss, defined as losing 20% or more of body weight, was achieved by 55% of patients. This is a particularly impressive statistic, as achieving such a high percentage of body weight loss was previously only commonly seen with bariatric surgery. These results showcase tirzepatide's potential to help a large number of individuals reach significant weight loss goals.

Long-Term Maintenance of Weight Loss

The effectiveness of tirzepatide also extends to the maintenance of weight loss over time. The SURMOUNT-4 randomized clinical trial, for example, investigated the continued treatment with tirzepatide for the maintenance of weight reduction in adults with obesity. This study focused on whether the weight lost could be sustained with ongoing treatment, a critical aspect of chronic weight management. Long-term studies are essential because obesity is a chronic disease, and maintaining weight loss often proves to be as challenging as losing it initially. The findings from such trials help to understand the sustained benefits of tirzepatide treatment. More details on the SURMOUNT-4 trial are available on the JAMA Network website Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The.

The mechanism behind this sustained weight loss lies in tirzepatide's dual action on GLP-1 and GIP receptors. As discussed, these hormones help regulate appetite, slow gastric emptying, and improve insulin sensitivity. By continuously activating these pathways, tirzepatide helps patients feel full for longer, reduce food intake, and better manage their metabolism, which all contribute to preventing weight regain. The consistency of the once-weekly dosing also supports long-term adherence, which is vital for maintaining the positive effects. The ability of tirzepatide to help patients not only lose a significant amount of weight but also maintain that loss over an extended period positions it as a highly effective treatment option for individuals struggling with obesity. This sustained efficacy makes it a powerful tool in addressing the chronic nature of obesity and its associated health risks.

What Are the Common Side Effects of Tirzepatide?

Like all medications, tirzepatide, found in both Zepbound and Mounjaro, can cause side effects. Most of these are mild to moderate and often involve the gastrointestinal system. Understanding these common side effects and how to manage them can help patients navigate their treatment journey more comfortably. It's important to remember that not everyone experiences these side effects, and their severity can vary from person to person.

Gastrointestinal Side Effects

The most frequently reported side effects of tirzepatide are gastrointestinal in nature. These include:

Nausea: This is one of the most common side effects, affecting between 12-22% of patients. Nausea can range from a mild queasy feeling to more significant discomfort.
Diarrhea: Experienced by 12-16% of patients, diarrhea can also be a common occurrence, particularly when first starting the medication or increasing the dose.
Vomiting: Around 6-13% of patients report vomiting. While less common than nausea, it can be more disruptive if it prevents fluid intake.
Constipation: Conversely, some patients may experience constipation, affecting 6-9% of individuals. This highlights the varied impact tirzepatide can have on bowel function.
Stomach pain: Abdominal discomfort or stomach pain is reported by 8-11% of patients. This can sometimes accompany other gastrointestinal symptoms.
Decreased appetite: While often a desired effect for weight loss, a decreased appetite can also be considered a side effect if it leads to inadequate nutritional intake, affecting 5-11% of patients.

These side effects often occur as the body adjusts to the medication, especially during the initial weeks of treatment or when the dose is increased. They are a direct result of how tirzepatide works, particularly its effect on slowing gastric emptying and influencing gut hormones. For many patients, these symptoms tend to lessen over time as their system adapts. To see how these rates compare against the newer triple agonist, read our retatrutide side effects breakdown by system and dose.

Management Strategies for Common Side Effects

Managing common side effects is crucial for patient comfort and adherence to treatment. Several strategies can help alleviate these symptoms:

Start with small, frequent meals: Eating smaller portions more often can reduce the burden on the digestive system, potentially lessening nausea and stomach discomfort.
Avoid high-fat, greasy foods: Fatty foods take longer to digest and can exacerbate gastrointestinal symptoms like nausea and stomach pain. Opting for leaner, easily digestible foods can be beneficial.
Stay well-hydrated: Drinking plenty of fluids, especially water, is important to prevent dehydration, particularly if experiencing diarrhea or vomiting. Staying hydrated can also help manage constipation.
Take with food if nausea occurs: For some individuals, taking the medication with a meal, rather than on an empty stomach, might help reduce feelings of nausea.
Consider anti-nausea medications if severe: If nausea becomes severe and significantly impacts daily life, a healthcare provider might recommend over-the-counter or prescription anti-nausea medications. It is important to discuss this with a doctor before starting any new medication.

By implementing these management strategies, many patients can continue their tirzepatide treatment with fewer disruptions. Regular communication with your healthcare provider is essential to discuss any persistent or worsening side effects and to ensure the treatment plan remains appropriate for your needs. Understanding that these are common and often manageable aspects of the treatment can help patients prepare and respond effectively. The experience with GLP-1 agonists, including tirzepatide, often involves these types of gastrointestinal adjustments as the body adapts to the medication's effects on the digestive system and appetite signals GLP-1 agonists and weight loss.

What Are the Serious Side Effects and Contraindications?

While common side effects of tirzepatide are usually manageable, it is crucial to be aware of the more serious potential side effects and specific situations where the medication should not be used, known as contraindications. These serious risks are important considerations that healthcare providers discuss with patients before starting treatment. The FDA has issued warnings for certain conditions, emphasizing the need for careful patient selection and monitoring.

Black Box Warning for Thyroid C-Cell Tumors

Tirzepatide carries a black box warning regarding the risk of thyroid C-cell tumors. A black box warning is the strongest warning that the FDA requires for prescription drugs, indicating serious or life-threatening risks. Studies in rodents have shown that tirzepatide can cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). While it is unknown whether tirzepatide causes these tumors in humans, this risk means that the medication is not recommended for individuals with a personal or family history of medullary thyroid carcinoma. It is also contraindicated for patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a genetic condition that predisposes individuals to MTC. Patients should be counseled on the potential risk of MTC and advised to report symptoms of thyroid tumors, such as a lump in the neck, hoarseness, or difficulty swallowing, to their doctor immediately.

Other Serious Side Effects

Beyond the black box warning, several other serious side effects have been identified with tirzepatide:

Acute pancreatitis: This is a serious inflammation of the pancreas. Patients should be aware of symptoms such as severe abdominal pain that does not go away, possibly radiating to the back, with or without vomiting. If these symptoms occur, immediate medical attention is necessary. Tirzepatide should be used with caution in patients with a history of pancreatitis.
Acute gallbladder disease: This can include gallstones or inflammation of the gallbladder (cholecystitis). Symptoms might include severe pain in the upper right abdomen, nausea, vomiting, and fever.
Diabetic retinopathy complications: In some patients with a history of diabetic retinopathy (damage to the blood vessels in the retina due to diabetes), tirzepatide treatment, especially rapid improvements in blood sugar control, may lead to temporary worsening of this condition. Regular monitoring of eye health is recommended for these patients.
Acute kidney injury: There have been reports of acute kidney injury in patients treated with GLP-1 receptor agonists, including tirzepatide. This risk is often associated with severe gastrointestinal side effects like vomiting and diarrhea leading to dehydration. Staying well-hydrated is crucial to mitigate this risk.

Contraindications

Certain conditions make tirzepatide unsuitable for use. These contraindications are critical for patient safety:

Personal or family history of medullary thyroid carcinoma (MTC): As mentioned with the black box warning, the risk of thyroid C-cell tumors makes this medication unsafe for these individuals.
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2): This genetic syndrome increases the risk of MTC, so tirzepatide is contraindicated.
Type 1 diabetes: Mounjaro, specifically, is not approved for use in individuals with type 1 diabetes. It is designed to work by stimulating insulin release when blood glucose levels are elevated, a mechanism not typically effective or safe for type 1 diabetes patients who require exogenous insulin.
Hypersensitivity to tirzepatide: Any patient with a known severe allergic reaction to tirzepatide or any of its components should not use the medication. Symptoms of a severe allergic reaction can include swelling of the face, lips, tongue, or throat, difficulty breathing or swallowing, severe rash, or dizziness.

It is important for patients to have a thorough discussion with their healthcare provider about their full medical history, including any family history of specific conditions, before starting tirzepatide. Regular monitoring during treatment is also recommended to detect any potential serious side effects early.

When Should You Contact Your Doctor?

Knowing when to seek medical attention is critical for anyone taking tirzepatide. While many side effects are common and manageable, certain symptoms can indicate a more serious condition requiring immediate professional evaluation. Being proactive and recognizing these warning signs can help ensure patient safety and prevent potential complications.

Urgent Medical Attention for Severe Symptoms

There are specific symptoms that warrant immediate medical attention. These signs suggest a potentially serious adverse event that should not be ignored:

Severe abdominal pain that doesn't go away: This is a key symptom of acute pancreatitis. The pain might be constant and intense, possibly radiating from the stomach area to the back. If you experience such pain, especially if it is severe and persistent, you should seek urgent medical care. This type of pain differs from the mild stomach discomfort sometimes experienced as a common side effect.
Persistent vomiting preventing fluid intake: While some vomiting can be a common side effect, if it becomes persistent and prevents you from keeping down fluids, it can lead to dehydration and acute kidney injury. This situation requires immediate medical attention to prevent serious dehydration and electrolyte imbalances.
Signs of pancreatitis (severe stomach pain radiating to back): As mentioned, severe, unrelenting stomach pain that spreads to your back is a hallmark symptom of pancreatitis. This condition can be life-threatening and requires prompt diagnosis and treatment. Do not delay in contacting your doctor or emergency services if you experience these symptoms.
Symptoms of thyroid tumors (lump in neck, hoarseness, difficulty swallowing): Given the black box warning for the risk of thyroid C-cell tumors, any new lump or swelling in your neck, persistent hoarseness, or difficulty swallowing could be signs of a thyroid tumor. These symptoms should be reported to your doctor right away for evaluation. Early detection is important for managing such conditions.
Severe allergic reactions: If you experience any symptoms of a severe allergic reaction (hypersensitivity) to tirzepatide, such as swelling of your face, lips, tongue, or throat, difficulty breathing or swallowing, a severe rash or itching, or dizziness and fainting, you must seek immediate medical help. These reactions can be life-threatening and require urgent intervention.

Importance of Ongoing Monitoring

Beyond these immediate concerns, regular monitoring is recommended throughout tirzepatide treatment. This includes routine check-ups and discussions with your healthcare provider about any new or worsening symptoms. Patients should maintain open communication with their doctor, reporting any changes in their health status or any side effects they experience, even if they seem minor. This ongoing dialogue allows healthcare providers to adjust treatment plans, offer advice on managing side effects, and monitor for any signs of serious complications. For instance, if you have a history of pancreatitis, your doctor will likely exercise caution and monitor you more closely during treatment. Similarly, patients with diabetic retinopathy may require regular eye examinations to monitor for complications. Being vigilant and working closely with your healthcare team is essential for safe and effective treatment with tirzepatide.

Does Insurance Cover Zepbound and Mounjaro Differently?

Yes, insurance coverage for Zepbound and Mounjaro often differs significantly, primarily because of their distinct FDA-approved indications. Even though both medications contain the same active ingredient, tirzepatide, the purpose for which they are prescribed heavily influences whether and how insurance companies will cover them. Understanding these differences is crucial for patients and providers navigating treatment options and associated costs.

Coverage Based on FDA Approval

The primary factor driving insurance coverage differences is the FDA approval for each medication.

Mounjaro: This medication is FDA-approved for the treatment of type 2 diabetes. As diabetes is considered a chronic medical condition, many insurance plans typically include benefits for diabetes medications. Therefore, Mounjaro is more likely to be covered under a patient's diabetes benefits. For individuals with a confirmed diagnosis of type 2 diabetes, obtaining insurance approval for Mounjaro is generally more straightforward, provided they meet other criteria set by their specific plan, such as prior authorization requirements or step therapy protocols. The goal of Mounjaro is to improve glycemic control, and insurance providers recognize this as a medically necessary treatment for diabetes management.
Zepbound: In contrast, Zepbound is FDA-approved for chronic weight management in adults with obesity or those who are overweight with at least one weight-related condition. In 2024, it also received approval for moderate-to-severe obstructive sleep apnea in adults with obesity. While obesity is a recognized chronic disease, insurance coverage for weight loss medications can be much more variable and restrictive. Many insurance plans do not have comprehensive weight management benefits, or they may have strict criteria for coverage, such as requiring participation in a supervised weight loss program or a certain BMI threshold with specific comorbidities. Therefore, Zepbound may face more restrictions or require specific weight management benefits that are not universally offered across all insurance policies. This can make access to Zepbound more challenging for some patients compared to Mounjaro.

Impact of Diagnosis and Treatment Goals

The patient's diagnosis and the specific treatment goals play a key role in prescribing decisions and subsequent insurance coverage.

If a patient has type 2 diabetes, a healthcare provider can prescribe Mounjaro, and it will likely fall under diabetes medication coverage. The potential for weight loss with Mounjaro would be considered a beneficial secondary effect, but the primary reason for prescribing would be diabetes management.
If a patient has obesity or is overweight with a weight-related condition, but does not have type 2 diabetes, Zepbound would be the appropriate prescription for weight management. In this scenario, insurance coverage would depend entirely on whether the patient's plan includes benefits for obesity treatment.

This distinction means that even if a patient with type 2 diabetes experiences significant weight loss on Mounjaro, and a patient without diabetes achieves similar weight loss on Zepbound, their insurance coverage pathways would be different. The "Key Takeaways" from MyorThrive emphasize this: "Insurance typically favors Mounjaro for diabetes, while Zepbound may face more restrictions for weight loss, making diagnosis and treatment goals key to prescribing decisions" Zepbound vs. Mounjaro: A Comparison for Weight Management and Diabetes Control. Patients are advised to thoroughly check their individual insurance plans and discuss coverage details with their healthcare provider and insurance company to understand potential out-of-pocket costs and requirements for prior authorization. Lilly provides resources for finding clinical trials and learning about their research, which can sometimes include information on patient access programs, though this doesn't directly address commercial insurance coverage Find Lilly Clinical Trials | Learn About Our Research.

Frequently Asked Questions

Are Zepbound and Mounjaro the same medication?

Yes, Zepbound and Mounjaro contain the exact same active ingredient: tirzepatide. They are both injectable prescription medications that work by mimicking the GLP-1 and GIP gut hormones to manage blood sugar, increase insulin production, and promote satiety. The key difference lies in their FDA approvals: Mounjaro is approved for type 2 diabetes, while Zepbound is approved for chronic weight management in adults with obesity or those who are overweight with at least one weight-related condition, and for moderate-to-severe obstructive sleep apnea in adults with obesity.

What is the average weight loss observed with tirzepatide?

In clinical trials, patients taking tirzepatide at the 15 mg dose achieved an average weight loss of 20.9% of their body weight over a 72-week period. This compares to only a 3.1% weight loss in patients receiving a placebo during the same time. These trials also showed that 91% of patients achieved at least 5% weight loss, and 55% achieved 20% or more weight loss, demonstrating its high efficacy for significant weight reduction.

What are the most common side effects of tirzepatide?

The most common side effects of tirzepatide for both Zepbound and Mounjaro are typically gastrointestinal. These include nausea, experienced by 12-22% of patients, and diarrhea, reported by 12-16% of patients. Other common side effects are vomiting (6-13%), constipation (6-9%), stomach pain (8-11%), and decreased appetite (5-11%). These side effects often lessen over time and can be managed with dietary adjustments like small, frequent meals and avoiding high-fat foods.

Can tirzepatide be used by people with type 1 diabetes?

No, tirzepatide (Mounjaro and Zepbound) is not recommended for individuals with type 1 diabetes. Mounjaro is specifically contraindicated for type 1 diabetes. This medication is designed to improve blood sugar control by stimulating insulin release when blood glucose levels are elevated and by improving insulin sensitivity, mechanisms that are not appropriate or effective for type 1 diabetes, which requires external insulin administration due to the body's inability to produce insulin.

Why do Zepbound and Mounjaro have different FDA approvals if they contain the same active ingredient?

Zepbound and Mounjaro have different FDA approvals because the clinical trials submitted for their approval focused on different primary outcomes. Mounjaro's trials primarily demonstrated efficacy in improving glycemic control for type 2 diabetes. Zepbound's trials, known as the SURMOUNT trials, specifically evaluated its effectiveness for chronic weight management and later for obstructive sleep apnea. Although they share the same active ingredient and mechanism of action, the specific conditions they are approved to treat dictate their brand names and usage guidelines.